ERBB2 and breast cancer: Conversely, the hyperactivity of HER2 (or the HER2 downstream signaling pathway) may interfere with ER expression and activity, thus representing a potential escape pathway in HR+ BC overexpressing HER2 and determining a state of de novo endocrine resistance [20].